Analysis of genetic polymorphisms and mRNA expression of DRD3 and HTR2A in bruxism Authors: Yosra Gassara, Hajer Foddha, Saoussen Chouchene, Sarra Nasri, Rim Kallala, Amel Haj Khelil, Mohsen Hassin, Hassen Ben Abdennebi, Belhassen Harzallah Published: 2026 ABSTRACT BackgroundBruxism, characterized by the involuntary grinding or clenching of teeth, is influenced by genetic, psychological, and environmental factors. This study aimed to evaluate the role of DRD3 (rs6280) and HTR2A (rs6313) polymorphisms in bruxism and to investigate the expression of these genes to better understand their biological significance.MethodsThis case–control study included 82 bruxism patients and 87 controls. Diagnosis was based on clinical examination and non-instrumental criteria from the 2018 international consensus. Genotyping of HTR2A rs6313 and DRD3 rs6280 was performed using PCR-RFLP, and gene expression in peripheral blood was assessed by qPCR. Statistical analyses included chi-square tests, logistic regression, and mRNA expression analysis using the ΔΔCt method.ResultsA significant association was identified between bruxism and the rs6313 polymorphism of the HTR2A gene (p = 0.004; OR = 1.89 [1.23–2.92]), with the C allele associated with increased risk. Moreover, HTR2A mRNA expression was upregulated in individuals with bruxism. While no significant differences were observed in DRD3 rs6280 genotype distribution between cases and controls, the presence of the C allele appeared to increase susceptibility to sleep bruxism. In addition, DRD3 mRNA expression was downregulated in bruxism patients.ConclusionsThese findings highlight a significant association between bruxism and the rs6313 polymorphism of the HTR2A gene. Furthermore, increased HTR2A and decreased DRD3 expression support the involvement of serotonin and dopamine pathways in bruxism etiology, underscoring its multifactorial and complex nature.Clinical significanceThis study elucidates the genetic basis of bruxism, indicating a potential role of serotonin and dopamine signaling in its pathogenesis. Understanding genetic predisposition could aid in early detection, risk assessment, and targeted treatment development.Trial registrationClinicaltrials.gov ; trial registration number: NCT06457646 (13/06/2024).Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-026-08633-8. Background Bruxism is defined as a repetitive masticatory muscle activity characterized by clenching or grinding of the teeth and/or by bracing or thrusting of the mandible. It is a spectrum of oral behaviors that can occur during wakefulness or sleep [1]. Bruxism is currently regarded as a multifactorial behavior influenced by genetic, psychological, and physiological factors rather than a single disease entity. Its consequences vary widely, and there is no clear cause–effect relationship between bruxism and dental damage [2–5]. According to Lobbezoo’s paper, the assessment of bruxism involves non-instrumental and instrumental approaches [6]. Additionally, cut-off points are suggested to assess bruxism-related masticatory muscle activity along a continuum rather than relying on fixed numerical thresholds, given the complex interplay of clinical consequences and individual variability. Moreover, the grading system classifies bruxism as possible, probable, or definite based on self-report, clinical inspection, and instrumental assessment, providing a structured framework for diagnosis. Bruxism can lead to various consequences and complications, including dental damage such as fractures and tooth wear in severe cases, jaw pain leading to jaw muscle strain, temporomandibular joint disorders, and headaches. Excessive pressure on the teeth can make them more susceptible to decay and other dental problems [7–9]. Given the complex nature of this phenomenon, several researchers have investigated various contributing factors. These factors include the psychological characteristics of the individual, praxis, ventilatory disorder, sleep quality, inflammatory markers and hormonal disturbances [10]. Bruxism can arise from both hereditary factors and central factors, including neurological and psycho-emotional influences. These factors encompass various neurological and psychological aspects that contribute to the development of bruxism [11, 12]. Recent researches have explored the relationship between genetic factors and susceptibility to bruxism [13]. Various genetic studies have explored the relationship between the − 5-HTR2A polymorphism and susceptibility to bruxism, highlighting the multifaceted role of serotonin [14, 15]. Serotonin plays a central role in regulating sleep-wake cycles, motor activity, pain perception, cognitive functions, and social behaviors. Dysregulation of serotonin pathways has been linked to conditions such as anxiety, depression, and neuroticism, which are frequently observed in individuals with bruxism [16]. This has prompted studies on polymorphisms of serotonin receptor genes in bruxism patients. Dopamine pathways actively participate in essential physiological processes, including regulation of motor control, reward mechanisms, motivation, goal-directed behavior, wakefulness, sleep cycles, cognitive functions, mood modulation, stress responses, addictive behaviors, and drug addiction tendencies. These pathways play a fundamental role in various aspects of human behavior, cognition, and physiological functioning [17]. In this context, Oporto et al. demonstrated that functions regulated by dopamine pathways are involved in the etiology and symptomatology of bruxism suggesting a neurobiological link between dopaminergic dysfunction and this condition [18]. Based on these findings, investigating the role of single nucleotide polymorphisms (SNPs) in genes involved in dopaminergic transmission becomes particularly relevant, especially in relation to circadian variations observed in bruxism expression. Among these genes, DRD3, which encodes the dopamine D3 receptor, is of particular interest. This receptor is predominantly expressed in the limbic regions of the brain and is critically involved in emotional regulation, cognitive processes, and motor control. Notably, alterations in DRD3 function have been associated with both movement disorders and psychiatric conditions, further supporting its potential role in the pathophysiology of bruxism [19]. The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. It has been shown that the DRD3 rs6280 polymorphism results in a serine-to-glycine substitution, potentially altering dopamine receptor binding affinity. HTR2A rs6313, though synonymous, may influence gene expression or mRNA stability. These polymorphisms may modulate receptor activity and neurotransmission, affecting susceptibility to neurobehavioral conditions like bruxism. In this context we aimed to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism providing insight into genetic predispositions that need to be taken into account, making it essential to balance these factors in treatment strategies. Methods Study protocol This case–control study was conducted within the blood bank of the CHU Fattouma Bourguiba in Monastir (Tunisia) after authorization from the Ethics Committee of the Higher Institute of Biotechnology of Monastir (approval number CER-SVS/ISBM 011/2021). The study protocol was approved and registered in the ClinicalTrials.gov database (NCT06457646, 13 June 2024). Participants meeting specific inclusion criteria were selected after a thorough screening process. Bruxism was diagnosed based on the non-instrumental approach out lined in the international consensus on the assessment of bruxism by Lobbezoo et al. [6]. Diagnosis relied on a self-reported questionnaire including the following questions: “Do you grind your teeth during the day?”, “When you are awake, do you tend to tense your jaw muscles or clench your teeth?”, “Do you grind your teeth in your sleep?”, and “Has any one heard you grind your teeth in your sleep?”. Participants who affirmed these behaviors were further examined clinically to confirm bruxism-related signs such as dental wear facets, masseter hypertrophy, or tongue indentations, providing a standardized and reproducible diagnostic framework. Stress was evaluated through the question “Do you find your psycho-social environment stressful?”. Parafunctional habits (praxis) were assessed with questions such as “Do you breathe through your mouth?”, “Do you usually chew gum?”, “Do you tend to bite your cheek, lip, or objects?”, “Do you bite your nails?”, and “Do you press your tongue or lips tightly against your teeth?”. Sleep disorders were explored through “Do you have trouble sleeping?”, and ventilatory disorders with “Do you snore during sleep?” and “Do you wake up with a dry mouth?”. Participants were eligible if they met the criteria for primary (idiopathic) bruxism, defined as repetitive masticatory muscle activity without any identifiable medical, neurological, or pharmacological cause. Both sleep and awake bruxism phenotypes were included. Sleep bruxism was characterized by rhythmic or phasic grinding movements with tooth contact, typically reported by the participant or a bed partner, whereas awake bruxism involved sustained tooth clenching or bracing during wakefulness. Inclusion required self-reported or partner-reported episodes of grinding or clenching, corroborated by clinical signs such as tooth wear, masseter hypertrophy, or jaw muscle tenderness. Participants had to be over 18 years of age and provide both oral and written informed consent prior to enrollment. A comprehensive collection of clinical data was carried out through detailed interviews and clinical examinations using a standardized questionnaire developed for this study (available as supplementary material). Collected data included demographic information, medical history, and current medications. The clinical examination included exo- and endo-buccal assessments, evaluation of the dental formula, inspection of the oral mucosa and periodontium, and analysis of occlusion to identify potential malocclusions. To ensure the specificity of the study population, individuals presenting systemic diseases, orofacial dysfunction, acute neurodegenerative disorders such as Parkinson’s disease, or taking medications such as anxiolytics were excluded. In order to estimate the minimum sample size for our study, we used a web browser program, BiostaTGV (https://marne.u707.jussieu.fr/biostatgv/). This site, is developed by the Pierre Louis Institute of Epidemiology and Public Health (iPLESP, UMR S 1136) affiliated to INSERM and Sorbonne University. Using this site, the sample size calculation was based on an expected prevalence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) of 0.36 and 0.41, respectively [18, 20], with a power of 80% and a two-sided α of 0.05. At least 82 patients were needed in each group. Genetic analysis Blood samples were collected in an EDTA (EthyleneDiamineTetra-Acetic) tube (containing 3.2% sodium citrate). In addition to its anticoagulant role, EDTA preserves DNA integrity by chelating magnesium ions, thereby inhibiting DNase activity. Genotyping for DRD3 (25G > A; rs6280) and HTR2A (102 C > T; rs6313) was performed using PCR-RFLP analysis. Genomic DNA was extracted from peripheral blood lymphocytes following the salting-out method. Primers were designed using Primer3 software (https://primer3.ut.ee/). The PCR cycling conditions for both SNPs involved an initial denaturation step at 94 °C for 5 min, followed by 35 cycles consisting of denaturation at 94 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s. The process concluded with a final extension step at 72 °C for 10 min. Each reaction was carried out in a 25 µL volume, comprising 100 ng of genomic DNA, 0.2 mM of each dNTP, 0.8 mM MgCl2, 0.2 mM of each primer, 1xTaq polymerase buffer (Biobasic), and 1.25 U Taq DNA polymerase (Biobasic). Following PCR, the products underwent overnight incubation at 37 °C with the relevant restriction enzymes (Table 1). Subsequently, the digested PCR products were analyzed on a 3% agarose gel and visualized under UV light after staining with ethidium bromide. Table 1 includes information on primers, restriction enzymes, and product sizes. Table 1Primer sequences, enzymes used for RFLP, and fragment patterns analysisSNPPrimersEnzymeFragment length (bp)rs6280F: 3’AAATGTAACTAAGCAACCAAGCC5’R: 3’GCAGTAGGAGAGGGCATAGTA5’HaeIIICC: 35 + 50+129CT : 35 + 50+129 + 179TT : 35 + 179rs6313F : 3’GTTACAGAGTGTGGGTACATCAA 5’R : 3’TGGCAAGTGACATCAGGAAATA5’BspEICC: 245 + 202CT: 245 + 202+448TT: 448 Table 1Primer sequences, enzymes used for RFLP, and fragment patterns analysisSNPPrimersEnzymeFragment length (bp)rs6280F: 3’AAATGTAACTAAGCAACCAAGCC5’R: 3’GCAGTAGGAGAGGGCATAGTA5’HaeIIICC: 35 + 50+129CT : 35 + 50+129 + 179TT : 35 + 179rs6313F : 3’GTTACAGAGTGTGGGTACATCAA 5’R : 3’TGGCAAGTGACATCAGGAAATA5’BspEICC: 245 + 202CT: 245 + 202+448TT: 448 Primer sequences, enzymes used for RFLP, and fragment patterns analysis F: 3’AAATGTAACTAAGCAACCAAGCC5’ R: 3’GCAGTAGGAGAGGGCATAGTA5’ CC: 35 + 50+129 CT : 35 + 50+129 + 179 TT : 35 + 179 F : 3’GTTACAGAGTGTGGGTACATCAA 5’ R : 3’TGGCAAGTGACATCAGGAAATA5’ CC: 245 + 202 CT: 245 + 202+448 TT: 448 DRD3 and HTR2A expression analysis To control for circadian variability, blood samples were collected between 8:00 and 10:00 a.m. Total RNA was extracted from white blood cells using TRIzol reagent (Invitrogen). DNA was removed with DNase I treatment. RNA was quantified using a Nanodrop 2000c spectrophotometer, and cDNA was synthesized using reverse transcriptase (MMLV, ThermoScientific Invitrogen™, France). Quantitative real-time PCR (qPCR) was performed with StepOne software (Thermo Fisher Scientific). Specific primers for HTR2A and DRD3 are listed in Table 2. Duplicate reactions (20 µL) contained 10 µL SYBR® Green PCR Master Mix (Applied Biosystems™), 0.5 nM of each primer, 4 µL sterile water and 4 µL cDNA. β-actin served as the calibrator control. Cycling conditions were: 95 °C for 10 min, followed by 40 cycles of 95 °C for 45 s, annealing at 60 °C (β-actin, DRD3) or 56 °C (HTR2A) for 1 min, and 72 °C for 45 s. Melting curve analysis was performed by heating to 95 °C for 15 s, cooling to 60 °C, then stepwise heating to 95 °C with a ramp rate of 0.3 °C. Ct values were used to calculate ΔCt (Ct target – Ct reference). Fold change in expression was determined using the 2^−ΔΔCt method. Table 2List of primer sequences used in expression analysesGenePrimer sequences β-actin F 5’- AGACGCAGGATGGCATGGG − 3’R 5’-GAGACCTTCAACACCCCAGCC − 3’ DRD3 (rs6280) F 5’-AAATGTAACTAAGCAACCAAGCC − 3’R 5’-GCAGTAGGAGAGGGCATAGTA − 3’ HTR2A (rs6313) F 5’- GTTACAGAGTGTGGGTACATCAA − 3’R 5’- TGGCAAGTGACATCAGGAAATA − 3’ Table 2List of primer sequences used in expression analysesGenePrimer sequences β-actin F 5’- AGACGCAGGATGGCATGGG − 3’R 5’-GAGACCTTCAACACCCCAGCC − 3’ DRD3 (rs6280) F 5’-AAATGTAACTAAGCAACCAAGCC − 3’R 5’-GCAGTAGGAGAGGGCATAGTA − 3’ HTR2A (rs6313) F 5’- GTTACAGAGTGTGGGTACATCAA − 3’R 5’- TGGCAAGTGACATCAGGAAATA − 3’ List of primer sequences used in expression analyses F 5’- AGACGCAGGATGGCATGGG − 3’ R 5’-GAGACCTTCAACACCCCAGCC − 3’ DRD3 (rs6280) F 5’-AAATGTAACTAAGCAACCAAGCC − 3’ R 5’-GCAGTAGGAGAGGGCATAGTA − 3’ HTR2A (rs6313) F 5’- GTTACAGAGTGTGGGTACATCAA − 3’ R 5’- TGGCAAGTGACATCAGGAAATA − 3’ Statistical analysis Statistical analyses were conducted using SPSS® version 17.0 (SPSS, Chicago, IL, USA). The Kolmogorov–Smirnov test was applied to assess normality of continuous variables; normally distributed data were expressed as mean ± standard deviation and compared using the Student’s t-test, whereas non-normally distributed data were expressed as medians (1st–3rd quartiles) and compared using the Mann–Whitney U test. Gender distribution was compared using the χ² test. Allelic distributions were evaluated using two-sided independent-sample Student’s t-tests with Epi Info v.1.4.3 (CDC, Atlanta, USA), and genotype frequencies between cases and controls were compared using the χ² test, with Hardy–Weinberg equilibrium assessed by χ² goodness-of-fit. Genetic associations were examined through logistic regression under codominant, dominant, and recessive models using the SNPStats online tool (https://bioinfo.iconcologia.net/SNPstats). In these models, each genotype was analyzed separately (codominant), variant allele carriers were compared with wild-type homozygotes (dominant), or homozygous variants were compared with all other genotypes (recessive). Multivariate binary logistic regression was performed to evaluate associations between bruxism (dependent variable: presence = 1, absence = 0) and the genotypes of DRD3 rs6280 and HTR2A rs6313, adjusting for stress, oral parafunctional habits (praxis), sleep disorders, and ventilatory disorders. Awake and sleep bruxism were also analyzed as separate explanatory variables in exploratory models. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. To address multiple testing arising from three genetic models per SNP, the Benjamini–Hochberg false discovery rate (FDR) correction was applied. FDR-adjusted q-values are reported for multivariate analyses, and q < 0.05 was considered statistically significant, with significant results marked by an asterisk in the tables. Results A total of 169 participants (control group: 87; case group: 82) were included in this study. No significant differences in age distribution were observed between the two groups (median age: case group 36 [range: 18–59] vs. control group 32 [range: 18–59]; p = 0.253), nor in gender (sex ratio: case group 3.1 vs. control group 3.6; p = 0.565). Based on questionnaire responses, sleep bruxism was identified in 22 participants (13.4%), awake bruxism in 11 (6.7%), and both sleep and awake bruxism in 49 individuals (29.9%). Genotype distributions in the control group conformed to Hardy–Weinberg equilibrium for both rs6280 (p = 0.50) and rs6313 (p = 0.07). The allelic distributions and frequencies of DRD3 rs6280 and HTR2A rs6313 are presented in Table 3. No statistically significant differences were observed between T and C alleles of DRD3 rs6280 when comparing the control and case groups (p = 0.742), or when comparing the control group and the sleep bruxism group (p = 0.062). Table 3Allelic frequencies of rs6280 of DRD3 gene and rs6313 of HTR2A gene in the studied populationControl groupCase groupORp valueSNPAlleleNFrequencyNFrequencyrs6280 T 1000.57910.551.08 [0.70–1.66]0.742 C 740.43730.45rs6313 T 1050.6730.451.89 [1.23–2.92]0.004 C 690.4910.55 Table 3Allelic frequencies of rs6280 of DRD3 gene and rs6313 of HTR2A gene in the studied populationControl groupCase groupORp valueSNPAlleleNFrequencyNFrequencyrs6280 T 1000.57910.551.08 [0.70–1.66]0.742 C 740.43730.45rs6313 T 1050.6730.451.89 [1.23–2.92]0.004 C 690.4910.55 Allelic frequencies of rs6280 of DRD3 gene and rs6313 of HTR2A gene in the studied population For HTR2A rs6313, significant differences in allelic distribution were observed between cases and controls (p = 0.004; OR = 1.89, 95% CI: 1.23–2.92), with the C allele associated with increased risk of bruxism. Similarly, when comparing the sleep bruxism subgroup and controls, significant allelic differences were found (p = 0.011; OR = 2.41, 95% CI: 1.22–4.76) (Table 4). Table 4Allelic frequencies of rs6280 of DRD3 gene and rs6313 of HTR2A gene in the studied population (control and sleep bruxism)Control groupCase group(sleep bruxism)ORp valueSNPAlleleNFrequencyNFrequencyrs6280 T 1000.57180.411.95 [0.99–3.82]0.062 C 740.43260.59rs6313 T 1050.6170.392.41 [1.22–4.76]0.011 C 690.4270.61 Table 4Allelic frequencies of rs6280 of DRD3 gene and rs6313 of HTR2A gene in the studied population (control and sleep bruxism)Control groupCase group(sleep bruxism)ORp valueSNPAlleleNFrequencyNFrequencyrs6280 T 1000.57180.411.95 [0.99–3.82]0.062 C 740.43260.59rs6313 T 1050.6170.392.41 [1.22–4.76]0.011 C 690.4270.61 Allelic frequencies of rs6280 of DRD3 gene and rs6313 of HTR2A gene in the studied population (control and sleep bruxism) The distribution of DRD3 rs6280 genotypes showed no significant differences between the overall case and control groups (Table 5). However, in the sleep bruxism subgroup (n = 22), associations were observed in both codominant (raw p = 0.038; OR = 3.60, 95% CI: 1.00–12.95; q = 0.114) and recessive models (raw p = 0.011; OR = 3.94, 95% CI: 1.40–11.09; q = 0.066). These associations did not remain significant after FDR adjustment. Table 5Association of rs6280 of DRD3 gene and rs6313 of HTR2A with bruxism (All types) under different genetic modelsGenetic ModelGenotypeControl group (87)Case group(82)Univariate analysisMultivariate analysis*OR (95% CI)p-valueOR (95% CI)FDR-adjusted q-valuesrs6280CodominantT/T26 (29.9%)27 (32.9%)1.000.351.000.55C/T48 (55.2%)37 (45.1%)0.74 (0.37–1.48)0.68 (0.30–1.51)C/C13 (14.9%)18 (21.9%)1.33 (0.55–3.26)1.24 (0.44–3.47)DominantT/T26 (29.9%)27 (32.9%)1.000.671.000.56C/T-C/C61 (70.1%)55 (67.1%)0.87 (0.45–1.66)0.80 (0.37–1.71)RecessiveT/T-C/T74 (85.1%)64 (78%)1.000.241.000.55C/C13 (14.9%)18 (21.9%)1.60 (0.73–3.52)1.60 (0.66–3.88)rs6313CodominantT/T35 (40.2%)18 (21.9%)1.00 0.02** 1.00 0.01** C/T35 (40.2%)37 (45.1%)2.06 (0.99–4.28)1.68 (0.74–3.85)C/C17 (19.5%)27 (32.9%)3.09 (1.34–7.09)4.34 (1.60-11.76)DominantT/T35 (40.2%)18 (21.9%)1.00 0.009** 1.00 0.02** C/T-C/C52 (59.8%)64 (78%)2.39 (1.22–4.71)2.33 (1.35–7.54)RecessiveT/T-C/T70 (80.5%)55 (67.1%)1.00 0.04** 1.00 0.01** C/C17 (19.5%)27 (32.9%)2.02 (1.00-4.08)3.19 (1.35–7.54)*Odds ratio and p values were derived from logistic regression models after adjustment for stress, praxis, sleep disorder and ventilatory disorder. FDR-adjusted q-values computed using Benjamini–Hochberg per SNP (3 models; multivariate results). q < 0.05 considered significant**Values in boldface indicate statistical significance Table 5Association of rs6280 of DRD3 gene and rs6313 of HTR2A with bruxism (All types) under different genetic modelsGenetic ModelGenotypeControl group (87)Case group(82)Univariate analysisMultivariate analysis*OR (95% CI)p-valueOR (95% CI)FDR-adjusted q-valuesrs6280CodominantT/T26 (29.9%)27 (32.9%)1.000.351.000.55C/T48 (55.2%)37 (45.1%)0.74 (0.37–1.48)0.68 (0.30–1.51)C/C13 (14.9%)18 (21.9%)1.33 (0.55–3.26)1.24 (0.44–3.47)DominantT/T26 (29.9%)27 (32.9%)1.000.671.000.56C/T-C/C61 (70.1%)55 (67.1%)0.87 (0.45–1.66)0.80 (0.37–1.71)RecessiveT/T-C/T74 (85.1%)64 (78%)1.000.241.000.55C/C13 (14.9%)18 (21.9%)1.60 (0.73–3.52)1.60 (0.66–3.88)rs6313CodominantT/T35 (40.2%)18 (21.9%)1.00 0.02** 1.00 0.01** C/T35 (40.2%)37 (45.1%)2.06 (0.99–4.28)1.68 (0.74–3.85)C/C17 (19.5%)27 (32.9%)3.09 (1.34–7.09)4.34 (1.60-11.76)DominantT/T35 (40.2%)18 (21.9%)1.00 0.009** 1.00 0.02** C/T-C/C52 (59.8%)64 (78%)2.39 (1.22–4.71)2.33 (1.35–7.54)RecessiveT/T-C/T70 (80.5%)55 (67.1%)1.00 0.04** 1.00 0.01** C/C17 (19.5%)27 (32.9%)2.02 (1.00-4.08)3.19 (1.35–7.54)*Odds ratio and p values were derived from logistic regression models after adjustment for stress, praxis, sleep disorder and ventilatory disorder. FDR-adjusted q-values computed using Benjamini–Hochberg per SNP (3 models; multivariate results). q < 0.05 considered significant**Values in boldface indicate statistical significance Association of rs6280 of DRD3 gene and rs6313 of HTR2A with bruxism (All types) under different genetic models *Odds ratio and p values were derived from logistic regression models after adjustment for stress, praxis, sleep disorder and ventilatory disorder. FDR-adjusted q-values computed using Benjamini–Hochberg per SNP (3 models; multivariate results). q < 0.05 considered significant **Values in boldface indicate statistical significance For HTR2A rs6313, genotype distribution differed significantly between cases and controls (Table 5). The CC genotype was associated with increased bruxism susceptibility in the codominant (raw p = 0.021; OR = 3.09, 95% CI: 1.34–7.09; q = 0.063) and dominant (raw p < 0.001; OR = 2.39, 95% CI: 1.22–4.71; q = 0.015) models, with the dominant model remaining significant after FDR correction. In the sleep bruxism subgroup, significant associations were initially observed under codominant (raw p = 0.057) and recessive (raw p = 0.018; OR = 3.84, 95% CI: 1.21–12.17) models; after adjustment, only the recessive model retained significance (q = 0.027) (Table 6). Table 6Association of rs6280 of DRD3 gene and rs6313 of HTR2A with bruxism under different genetic models (control and sleep bruxism)Genetic ModelGenotypeControl group (87)Case group(22)**Univariate analysisMultivariate analysis*OR (95% CI)p-valueOR (95% CI)FDR-adjusted q-valuesrs6280CodominantT/T26 (29.9%)5 (22.7%)1.00 0.03** 1.000.07C/T48 (55.2%)8 (36.4%)0.87 (0.26–2.92)0.80 (0.22–2.87)C/C13 (14.9%)9 (40.9%)3.60 (1.00-12.95)3.39 (0.87–13.26)DominantT/T26 (29.9%)5 (22.7%)1.000.501.000.6C/T-C/C61 (70.1%)17 (77.3%)1.45 (0.48–4.34)1.35 (0.42–4.32)RecessiveT/T-C/T74 (85.1%)13 (59.1%)1.00 0.01** 1.00 0.02** C/C13 (14.9%)9 (40.9%)3.94 (1.40-11.09)3.91 (1.30–11.80)rs6313CodominantT/T35 (40.2%)4 (18.2%)1.000.0571.000.052C/T35 (40.2%)9 (40.9%)2.25 (0.63–7.99)2.03 (0.54–7.59)C/C17 (19.5%)9 (40.9%)4.63 (1.25–17.21)6.13 (1.44–26.11)DominantT/T35 (40.2%)4 (18.2%)1.00 0.04** 1.000.058C/T-C/C52 (59.8%)18 (81.8%)3.03 (0.94–9.71)3.02 (0.89–10.16)RecessiveT/T-C/T70 (80.5%)13 (59.1%)1.00 0.04** 1.00 0.02** C/C17 (19.5%)9 (40.9%)2.85 (1.05–7.76)3.99 (1.25–12.72)*Odds ratio and p values were derived from logistic regression models after adjustment for stress, praxis, sleep disorder and ventilatory disorder, ** The case group includes only participants with self-reported sleep bruxism. FDR-adjusted q-values computed using Benjamini–Hochberg per SNP (3 models; multivariate results). q < 0.05 considered significant ** Values in boldface indicate statistical significance Table 6Association of rs6280 of DRD3 gene and rs6313 of HTR2A with bruxism under different genetic models (control and sleep bruxism)Genetic ModelGenotypeControl group (87)Case group(22)**Univariate analysisMultivariate analysis*OR (95% CI)p-valueOR (95% CI)FDR-adjusted q-valuesrs6280CodominantT/T26 (29.9%)5 (22.7%)1.00 0.03** 1.000.07C/T48 (55.2%)8 (36.4%)0.87 (0.26–2.92)0.80 (0.22–2.87)C/C13 (14.9%)9 (40.9%)3.60 (1.00-12.95)3.39 (0.87–13.26)DominantT/T26 (29.9%)5 (22.7%)1.000.501.000.6C/T-C/C61 (70.1%)17 (77.3%)1.45 (0.48–4.34)1.35 (0.42–4.32)RecessiveT/T-C/T74 (85.1%)13 (59.1%)1.00 0.01** 1.00 0.02** C/C13 (14.9%)9 (40.9%)3.94 (1.40-11.09)3.91 (1.30–11.80)rs6313CodominantT/T35 (40.2%)4 (18.2%)1.000.0571.000.052C/T35 (40.2%)9 (40.9%)2.25 (0.63–7.99)2.03 (0.54–7.59)C/C17 (19.5%)9 (40.9%)4.63 (1.25–17.21)6.13 (1.44–26.11)DominantT/T35 (40.2%)4 (18.2%)1.00 0.04** 1.000.058C/T-C/C52 (59.8%)18 (81.8%)3.03 (0.94–9.71)3.02 (0.89–10.16)RecessiveT/T-C/T70 (80.5%)13 (59.1%)1.00 0.04** 1.00 0.02** C/C17 (19.5%)9 (40.9%)2.85 (1.05–7.76)3.99 (1.25–12.72)*Odds ratio and p values were derived from logistic regression models after adjustment for stress, praxis, sleep disorder and ventilatory disorder, ** The case group includes only participants with self-reported sleep bruxism. FDR-adjusted q-values computed using Benjamini–Hochberg per SNP (3 models; multivariate results). q < 0.05 considered significant ** Values in boldface indicate statistical significance Association of rs6280 of DRD3 gene and rs6313 of HTR2A with bruxism under different genetic models (control and sleep bruxism) *Odds ratio and p values were derived from logistic regression models after adjustment for stress, praxis, sleep disorder and ventilatory disorder, ** The case group includes only participants with self-reported sleep bruxism. FDR-adjusted q-values computed using Benjamini–Hochberg per SNP (3 models; multivariate results). q < 0.05 considered significant ** Values in boldface indicate statistical significance To further assess the relative contributions of the two SNPs, we performed a combined multivariate logistic regression including both DRD3 rs6280 and HTR2A rs6313 (Supplementary Table 1). The association of HTR2A rs6313 with bruxism remained robust and independent, whereas the association of DRD3 rs6280 was attenuated but remained suggestive. These findings confirm HTR2A rs6313 as the stronger independent predictor of bruxism risk in our cohort. After adjusting for covariates (stress, praxis, sleep disorder, and ventilatory disorder), associations between HTR2A rs6313 and bruxism remained significant under codominant (q = 0.015) and dominant (q = 0.0177) models. For the sleep bruxism subgroup, significance was retained only under the recessive model (q = 0.027). In contrast, no significant associations were found for DRD3 rs6280 after multiple testing corrections. No statistically significant associations were detected in the awake bruxism subgroup (n = 11) or the combined awake and sleep bruxism group (n = 49) (Supplementary Table 2). Bruxism and mRNA expression Relative mRNA expression levels were normalized to β-actin. A two-fold increase in HTR2A mRNA expression was observed in patients with bruxism compared to controls, whereas DRD3 expression was reduced in cases (Fig. 1). Fig. 1Bruxism and mRNA expression Bruxism and mRNA expression Discussion The research hypothesis suggesting that DRD3 (rs6280) and HTR2A (rs6313) polymorphisms play a significant role in the pathogenesis of bruxism has been accepted. Additionally, the mRNA expression of HTR2A and DRD3 has been implicated in the genesis of bruxism. Analyzing gene expression in blood or the assessment of RNA within blood cells serves as a valuable strategy for identifying biomarkers and investigating the underlying mechanisms of various diseases, including bruxism [21]. Research indicates that in approximately 80% of cases, blood cells exhibit a transcriptome similar to that of the brain [22]. For instance, Sullivan et al. discovered significant overlap in gene expression related to neurotransmitter receptors between blood cells and various brain tissues [23]. Our findings demonstrate a significant association between bruxism and the HTR2A gene rs6313 polymorphism, aligning with previous studies. For instance, Abe et al. identified the CC genotype of the SNP rs6313 of the HTR2A receptor gene as a risk factor for sleep bruxism in the Japanese population (p = 0.001), with the C allele presenting a significant risk (OR = 4.250, p = 0.004) [24]. Similarly, Cruz-Fierro et al. found that the C allele of rs6313 in the HTR2A gene was significantly associated with an increased risk of sleep bruxism in the Mexican population (OR = 4.250; 95% CI 1.599–11.297; p = 0.004) [25]. Additionally, in the study by Wieckiewicz et al., analysis of various SNPs indicated that the C allele of HTR2A rs6313 (p = 0.036) was associated with sleep bruxism [26]. While all the aforementioned studies have examined the relationship between HTR2A polymorphism and susceptibility to bruxism, no research to date has investigated the mRNA expression of genes involved in bruxism. The results of our study showed an association between bruxism and increased HTR2A mRNA expression. Serotonin, acting through its receptors, including HTR2A, modulates behavior and mood regulation [16]. The prefrontal cortex and hippocampal regions, where HTR2A is abundantly expressed, are crucial for emotional processing and motor control [27]. Disruption of serotonin signaling, as evidenced by altered HTR2A expression, may lead to aberrant neural activity contributing to bruxism. This aligns with existing knowledge about the involvement of serotonin receptors in motor control and nociception, as well as in various neurological conditions such as depression, stress, anxiety disorders, and medication-induced bruxism [28]. Therefore, our findings support the effect of HTR2A mRNA expression on the genesis of bruxism, although further expression studies are needed to confirm this. Concerning the DRD3 rs6280 polymorphism, the distribution of various genotypes among individuals with bruxism showed no statistically significant differences between the control and case groups. However, our findings suggest that the presence of the C allele is associated with a higher susceptibility to developing sleep bruxism. Sleep bruxism is considered a distinct entity due to putative differences in its etiology and phenotypic variance [29]. Notably, the association between DRD3 rs6280 and bruxism was observed only in the pure sleep bruxism subgroup, but not in awake or combined bruxism groups. This pattern supports the hypothesis that genetic susceptibility may differ between bruxism phenotypes, with DRD3 rs6280 exerting a stronger effect in sleep bruxism. These findings align with those reported by Oporto et al., who found a significant association between the C allele of the DRD3 receptor gene rs6280 and an increased risk of sleep bruxism (p = 0.02) [18]. This association reinforces the hypothesis that dopaminergic dysregulation may underlie certain forms of bruxism, particularly those with circadian manifestations. The dopamine D3 receptor, encoded by the DRD3 gene, is predominantly expressed in the limbic system and basal ganglia, key brain regions involved in motor control, emotion regulation, and reward processing. Alterations in DRD3 function or expression have been implicated in several neurological and psychiatric disorders, including Parkinson’s disease, schizophrenia, substance use disorders, bipolar disorder, and depression [30, 31]. In our study, we observed a decrease in DRD3 mRNA expression among individuals with bruxism. Although DRD3 dysregulation has been linked to other neuropsychiatric conditions, this is, to our knowledge, the first study to report reduced DRD3 expression in the context of bruxism. This novel finding suggests that altered dopaminergic signaling, specifically involving DRD3, may contribute to involuntary motor activity during sleep, supporting a mechanistic role for dopamine pathways in the pathophysiology of sleep bruxism. In our analysis, although we assessed overall expression levels, we did not stratify the results by genotype (e.g., CC/CT vs. TT) due to limited statistical power. To further elucidate the relationship between DRD3 expression and genetic variation, future studies with larger cohorts are needed to explore genotype-specific expression patterns and better understand their potential role in the pathophysiology of bruxism. Taken together, these genetic findings carry significant implications for therapeutic strategies. A better understanding of the molecular and genetic underpinnings of bruxism may ultimately enable the development of personalized treatment plans, particularly in dental practice. Genetic profiling allows dental professionals to better assess a patient’s risk and customize treatment plans, including targeted interventions like stress management for anxiety-related bruxism and optimized pharmacotherapy based on genetic responses to medications. This personalized approach not only enhances patient engagement but also improves outcomes in managing bruxism and its consequences, such as temporomandibular disorders and dental caries [32, 33]. It is important to acknowledge that psychosocial stress and anxiety may share common neurogenetic pathways involving serotonergic and dopaminergic signaling. This overlap could represent a confounding factor influencing both bruxism expression and genetic predisposition [3, 34]. Future studies incorporating psychometric and neuroendocrine parameters are warranted. Despite the findings of our study, the lack of consensus in bruxism etiology underscores the need for further clinical trials. Additional studies using polysomnographic diagnosis and diverse ethnicities are essential to confirm the involvement of serotonin and dopamine receptor gene polymorphisms in bruxism etiology. Bruxism has recently been described as a ‘medical gateway for dentistry’ [5], bridging dental, neurological, and psychological health. This perspective reinforces the relevance of our findings, as understanding genetic predispositions, including HTR2A and DRD3 variations, may clarify the multifactorial and systemic nature of bruxism and support interdisciplinary management approaches. Moreover, educational and terminological strategies are essential to advance bruxism research and care [35]. Standardizing definitions and improving clinician and patient education enhance diagnostic consistency, interdisciplinary communication, and personalized management. Limitations This study has several limitations that should be acknowledged. The diagnosis of bruxism relied on self-reported questionnaires combined with clinical examination rather than instrumental methods such as electromyography or polysomnography. While this approach is practical for large-scale studies, it may reduce diagnostic accuracy compared with gold-standard methods. In addition, the criteria used were based on non-instrumental guidelines proposed by Lobbezoo et al. ([6] rather than the recently published Standardized Tool for the Assessment of Bruxism (STAB), which provides a structured, multidimensional evaluation integrating instrumental, clinical, and self-reported data [36]. As our study was designed prior to the introduction of STAB, it could not be implemented. Future studies should adopt STAB-based or equivalent standardized protocols to improve diagnostic consistency and comparability [36–38]. The relatively small sample size may have limited the statistical power, particularly in subgroup analyses, and could explain the lack of significance observed in some comparisons (e.g., Table 6). Logistic regression analyses included multiple explanatory variables, which increases the risk of type I error due to multiple testing. Although false discovery rate (FDR) correction was applied across the three genetic models per SNP, residual false positives cannot be entirely excluded. Findings, particularly for rs6313, should therefore be interpreted with caution and confirmed in larger, independent cohorts. Methodologically, the number of cases in the sleep bruxism subgroup (n = 22) was insufficient for a logistic regression model including five explanatory variables, violating the commonly accepted rule of thumb of 10 events per variable for model stability. As a result, the adjusted odds ratios and p-values for this subgroup are likely unstable and should be considered preliminary and hypothesis-generating. Finally, the classification into sleep, awake, and combined bruxism was based on questionnaire responses and clinical inspection. While this dichotomous grouping facilitates practical comparisons, it oversimplifies a continuum of muscle activity and may not fully capture the behavioral complexity of bruxism [34, 39, 40]. Conclusion In this study, we investigated the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism, as well as the mRNA expression levels of these genes. Our findings suggest a significant association between bruxism and the rs6313 polymorphism of the HTR2A gene, with the C allele conferring an increased risk of bruxism. Additionally, increased HTR2A mRNA expression was observed in individuals with bruxism, indicating a potential role of serotonin signaling in the pathogenesis of bruxism. While no statistically significant differences were found in the distribution of DRD3 rs6280 genotypes between control and case groups, our results suggest that the presence of the C allele may be associated with a higher susceptibility to developing sleep bruxism. Furthermore, decreased DRD3 mRNA expression was observed in individuals with bruxism, highlighting a potential involvement of dopamine pathways in the disorder. These findings underscore the complex interplay between genetic factors and bruxism etiology. Supplementary Information Supplementary Material 1: Supplementary Table 1: Results of Multivariate Analysis for DRD3 rs6280 and HTR2A rs6313, Each Adjusted for the Other SNP, Across Bruxism Subtypes. Supplementary Material 1: Supplementary Table 1: Results of Multivariate Analysis for DRD3 rs6280 and HTR2A rs6313, Each Adjusted for the Other SNP, Across Bruxism Subtypes. Supplementary Material 2: Supplementary Table 2: Overview of association p-values for DRD3 and HTR2A polymorphisms by bruxism subtype. Supplementary Material 2: Supplementary Table 2: Overview of association p-values for DRD3 and HTR2A polymorphisms by bruxism subtype. Supplementary Material 3 Supplementary Material 3